PATENT CLAIM ANALYSIS

Application Number: 16303846
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-06
Patent Classification: ["424", "174100"]

Abstract:
A method of sensitizing cancer to immunotherapy in a subject in need thereof includes administering to the subject a therapeutically effective amount of a CdK5 inhibitor to suppress immune checkpoint PD-L1.

Claim (Index 12):
The method of  claim 10 , further comprising administering a PD-1 binding antagonist and/or a PD-L1 binding antagonist in combination with the Cdk5 inhibitor, the PD-1 binding antagonist and/or a PD-L1 binding antagonist in inhibiting PD-1/PD-L1 interaction.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 98.0
- Lexical Diversity: 1.28
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15239524', '15239569', '14333375', '15748284', '14740876']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7354024756710426
- 35 USC 102 Novelty (BERT): 0.5273206242227209
- Combined Prediction Score: 0.7145942905262105
- Mean Citation Score: 335.182852
- Max Citation Score: 348.81326
- Similarity Product: 235.8867692293847

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test